Biological Evaluation of a Novel Anti-inflammatory Treatment in Immune-mediated Inflammatory Diseases

Centre Hospitalier Universitaire de Besancon150 enrolled

Overview

The aim of the study is to investigate in vitro the impact of a novel anti-inflammatory treatment on costimulatory molecules expressed on monocytes.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

150

Conditions

Inflammation

Interventions

Blood sampleBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Immune-mediated inflammatory disease (non-ST segment elevation myocardial infarction, Rheumatoid arthritis, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Crohn's disease, Ulcerative colitis, Cystic fibrosis, Psoriasis, Multiple sclerosis or major depressive episode) * Patient able to understand the reason of the study * Patient not opposed to the conservation of biological samples for scientific research Exclusion Criteria: * Pregnant woman * Subject without health insurance

Locations (1)

University Hospital

Besançon, France

Outcomes

Primary Outcomes

Expression of costimulatory molecules CD86, CD80, CD40 and class II (HLA-DR) on monocytes

Time frame: 24 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.